Cedric Francois Sells 2,824 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CEO Cedric Francois sold 2,824 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the transaction, the chief executive officer now directly owns 415,695 shares of the company's stock, valued at approximately $12,271,316.40. This trade represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cedric Francois also recently made the following trade(s):

• On Wednesday, January 22nd, Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total value of $412,356.93.
• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $179,288.90.

Apellis Pharmaceuticals Trading Down 1.8 %

APLS traded down $0.52 during trading on Monday, hitting $28.49. 1,501,925 shares of the stock were exchanged, compared to its average volume of 1,930,394. The firm has a 50 day simple moving average of $32.21 and a 200 day simple moving average of $32.76. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -14.03 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analysts' expectations of $200.00 million. During the same quarter in the previous year, the business earned ($1.17) earnings per share. The company's revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in APLS. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. True Wealth Design LLC purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $56,000. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after acquiring an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after acquiring an additional 781 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on APLS. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Robert W. Baird dropped their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Piper Sandler lowered their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company lowered their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).